CAS 163768-50-1
:N,N-Dimethyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine
CAS:Formel:C40H67N5O8Reinheit:99%Farbe und Form:SolidMolekulargewicht:745.9887Auristatin F
CAS:(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(Dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acidFormel:C40H67N5O8Reinheit:99%Molekulargewicht:745.99Auristatin F TFA Salt
CAS:Kontrolliertes ProduktStability Hygroscopic
Applications Auristatin F is an antimitotic auristatin derivative that has been shown as a potent antitumor agent.
References Doronina S.O., et al.: Bioconjugate Chem., 17, 114-124 (2006);Formel:C40H67N5O8•x(C2HF3O2)Farbe und Form:NeatMolekulargewicht:745.9911402Auristatin F TFA Salt
CAS:Auristatin F TFA salt is a potent antitumor agent that can be used for the treatment of solid tumours. It inhibits the growth of cancer cells by binding to epidermal growth factor (EGF) receptors and blocking the action of EGF. Auristatin F TFA salt has been shown to induce apoptosis in prostate cancer cells and can also act as a potential biomarker for tumour response. The drug is not toxic to healthy cells, but it is rapidly eliminated from the body due to its short half-life. Auristatin F TFA salt has been shown to have pharmacokinetic properties that are similar in mice, rats, and humans. This drug also binds monoclonal antibodies against EGFR, which may serve as an alternative treatment for cancer patients who develop resistance to temozolomide.
Formel:C40H67N5O8•(C2HF3O2)xReinheit:Min. 95%Molekulargewicht:745.99 g/molAuristatin F
CAS:Auristatin F is an effective inhibitor of microtubule and vascular damaging agent. Auristatin F can be used in antibody-drug conjugates.Formel:C40H67N5O8Reinheit:98.41% - 99.25%Farbe und Form:White SolidMolekulargewicht:745.99
